In recent years, the incidence of cancer has been increasing, posing a major threat to human health and life safety. According to the 2024 Global Cancer Statistics, the survival rate for liver cancer is only 22%. Liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, cholangiocarcinoma, and fibrolamellar carcinoma. Most of them are HCC. Primary liver cancer has become the fifth leading cause of cancer diagnosis in the world and the third leading cause of cancer death threatening human health (1). Currently, clinical treatments for liver cancer primarily include surgery, radiotherapy, and chemotherapy. However, liver cancer cells may evade the attack of human immune system and make themselves survive and proliferation in the host (2). In the context of hepatocellular carcinoma treatment, while surgery is commonly employed for tumor eradication, the presence of underlying conditions such as liver cirrhosis in most patients elevates surgical risks and the likelihood of recurrence (3, 4).

Recent studies have pointed to EVs, especially exosomes, as potential biomarkers for the diagnosis of liver cancer (5, 6). As the “carrier” of intercellular communication, exosomes are stable and rich in composition, which can effectively convey tumor information, including cell origin and gene mutation (7, 8). In the context of liver cancer, exosomes play pivotal roles by transmitting various bioactive molecules that regulate cancer cell proliferation, invasion, and metastasis processes (9, 10). The detection of exosomes in the blood of patients can achieve early diagnosis, condition monitoring, and prognosis assessment of liver cancer (11). Exosomes also hold promise in liver cancer therapy, serving as carriers for drug delivery to achieve precise treatment and potentially for immunotherapy applications by modulating immune cell activity within the tumor microenvironment to enhance anti-tumor immune responses (9, 12, 13). Liver cancer stem cell-derived exosomes in the microenvironment promote the growth, progression and metastasis of HCC by reducing cell apoptosis, increasing angiogenesis, enhancing metastatic invasiveness and inducing epithelial-mesenchymal transition (14, 15). Research on exosomes offer novel directions and hope for the diagnosis and treatment of liver cancer.

This review reviews the multiple roles of exosomes in liver cancer, including the initiation, progression, and metastasis of liver cancer, as well as their effects on angiogenesis, epithelial mesenchymal transformation (EMT), immune evasion, and drug resistance. This review aims to fill the knowledge gap in the current research on the biological functions and clinical applications of exosomes in liver cancer, delving into the regulatory mechanisms, signal transduction pathways, and potential clinical applications of exosomes in the process of liver cancer development and progression, providing new insights and directions for future research and clinical practice.

The study of exosomes is faced with the problem of low yield and insufficient purity. The separation techniques should be carefully selected according to the study objectives and sample characteristics (25).

The isolation and purification of exosomes refers to the various methods and technologies used to separate and purify exosomes from cell culture supernatants and biological fluids. The isolation and purification of exosomes involve techniques like ultracentrifugation, commercial kits (e.g., ExoQuick™), immunomagnetic bead separation, ultrafiltration, sucrose gradient centrifugation, polymer enrichment, size exclusion, field flow fractionation, microfluidic chips (26, 27). But all of them have certain limitations. Ultracentrifugation is a commonly used separation and purification method, and the use may lead to co-purification of non-exosome particles, which may affect the accuracy and interpretation of downstream applications. Ultracentrifugation works by separating particles based on their size and density differences under centrifugal force. However, due to the wide range of exosome sizes, about 30 to 150 nm, and the overlap with other EVs and protein particles, non-exosome particles easily settle down with the exosomes during ultracentriollation (28). The ExoQuick™ kit may isolate at a relatively low purity and may contain non-exosomal components. Because the separation method is mainly based on polymer precipitation method, the obtained exosome samples may contain more non-exosome components such as proteins and lipid particles, with low purity. This lack of purity may interfere with high-precision molecular analyses such as proteomics or RNA sequencing (29). Immunomagnetic bead separation method separates exosomes by specifically binding the antigens on the surface of exosomes with specific antibodies, achieving rapid separation of exosomes, but the cost is relatively higher and requires specific antibodies and magnetic beads (30). Ultrafiltration, a classical method for exosome isolation, is suitable for purifying exosomes from large volumes of culture medium. It relies on size differences to separate exosomes, offering a simple process without complex steps or expensive reagents. Ultrafiltration efficiently preserves the integrity and biological activity of exosomes, enabling large-scale preparation for clinical research and applications. However, smaller exosomes may be lost during filtration, depending on the choice and performance of the filter membrane. Advanced methods such as microfluidics use micrometer scale fluid manipulation to efficiently separate exosomes by their physical size, density, and charge characteristics. Compared with traditional methods, it has the advantages of less sample consumption, shorter separation time and automatic operation, which is especially suitable for high-throughput and rapid isolation of exosomes in clinical applications. However, microfluidic technology still faces some problems in practical applications, such as high cost, low popularity, relatively low device throughput, and no unified standard (31, 32) (Table 1).

Tumor microenvironment (TME) is a complex environment composed of tumor cells, innate and adaptive immune cells, endothelial cells, cancer-associated fibroblasts, vasculature, and the surrounding matrix, among other cell types (45). The impact of tumors on the microenvironment is complex and varied, including metabolic changes, angiogenesis, immune suppression, and extracellular matrix remodeling. These effects work together to provide favorable conditions for the survival, proliferation, invasion, and metastasis of tumor cells (6). Exosomes can regulate immune cells in the tumor microenvironment through a variety of ways. For example, exosomes secreted by liver cancer cells can bind to PD-1 on the surface of tumor infiltrating lymphocytes (TILs) by carrying PD-L1, and inhibit the activation of T cells, thereby promoting tumor immune escape. In addition, molecules such as microRNA-21 in exosomes can inhibit anti-tumor immune response and promote the maintenance of inflammatory microenvironment by regulating signaling pathways in immune cells, such as NF-κB and STAT3. At the same time, exosomes can also induce the proliferation of immunosuppressive regulatory T cells (Tregs) by carrying cytokines such as transforming growth factor-beta (TGF-β), which further weakens the immune surveillance function (46). Hepatocellular carcinoma has complex and diverse cell-to-cell communication mechanisms in its microenvironment. These communication methods play a crucial role in regulating the occurrence, proliferation, invasion, apoptosis, immune evasion, angiogenesis,EMT of hepatocellular carcinoma cells (47). These cells interact with each other, promoting or inhibiting the occurrence and development of tumors. When tumor cells enter the TME, they stimulate immune cells and other immune-related cells in the TME, promoting immune evasion and tumor progression (48). A recent study has shown that exosomes secreted by hepatocellular carcinoma cells can promote the activation of tumor-associated fibroblasts (CAFs) by carrying specific micrornas, such as miR-1247-3p, and then enhance the invasion and metastasis of tumors (49). In addition, another study found that exosome-mediated communication by carrying lncRNA TUC339 could inhibit natural killer (NK) cell activity in the liver, thereby helping tumor cells to evade immune surveillance and promote tumor growth in vivo (50). These in vivo studies provided direct evidence for the specific mechanism of exosomes in the progression of HCC, demonstrating the importance of exosomes in regulating the HCC microenvironment and promoting tumor malignant behavior (Figure 2).

Liver tumor-derived exosomes can activate endothelial cells to support liver tumor angiogenesis and thrombosis. At the same time, they can transform fibroblasts and bone marrow mesenchymal stem cells into myofibroblasts, further promoting the generation of liver tumor blood vessels and metastasis (51). Yang et al. studied that HCC-derived exosomal miR-3174 can be transmitted to human umbilical vein endothelial cells (HUVECs) and can induce HCC angiogenesis and increase its ex vivo permeability. It can also promote its metastasis (52).

Targeting exosome-mediated angiogenic pathways may provide an effective complementary strategy for antiangiogenic therapy. Exosomes secreted by liver cancer cells can carry angiogenic molecules, such as VEGF, miR-210, miR-21 and promote angiogenesis by activating signaling pathways in endothelial cells, such as PI3K/AKT and MAPK pathways. These exosome-mediated molecules are different from the targets of existing anti-VEGF therapies and provide new mechanisms of angiogenesis regulation (53–55). Jiang et al. found that miR-30a-5p derived from ICCA can be transferred to endothelial cells and promote their recruitment and proliferation through an exosome dependent mechanism. Further induce angiogenesis and enhance vascular permeability (51).

The conclusions drawn from these various studies suggest that exosome-based strategies have broad application prospects in liver cancer vascular therapy. By adjusting the use of exosomes, a novel, targeted liver cancer treatment may be developed in the future (6, 56).

Exosomes affect the growth, migration and invasion of tumor cells in the microenvironment of HCC (57).

The PI3K/AKT pathway is one of the most frequently activated growth pathways in liver cancer cells, which can enhance cell proliferation and inhibit apoptosis by regulating cyclin and anti-apoptotic proteins (58). Studies have shown that miR-155 can inhibit SOCS1 through exosomes, and then activate the JAK/STAT signaling pathway to promote the proliferation of liver cancer cells and the inflammatory response in the tumor microenvironment (59). Further studies also revealed the interaction of exosomal mirnas with other tumor-driven pathways such as Wnt/β-catenin and MAPK, whose activation provides growth and invasion advantages to HCC cells (60). Exosomes also play a role in gene expression regulation in HCC. Some research results show that UBXN9 plays a key role in promoting the stimulatory RNA-induced retinoic acid-inducible gene-I-interferon signaling pathway, which can induce effective anti-tumor T cell responses in liver tumorigenesis (61). Higher levels of miR-30a-5p are associated with higher microvascular density (MVD) and poorer prognosis. This suggests that miR-30a-5p may promote the growth and progression of liver cancer by affecting angiogenesis. Further research has found that hypoxia stress can induce the expression of HIF-1α in hepatocellular carcinoma cells, thereby enhancing the expression of miR-30a-5p (51). Additionally, research has found that miR-934 in exosomes derived from tumors can regulate the interaction between CRC cells and TAMs, thereby promoting the occurrence of CRLM (colorectal cancer liver metastasis) (62).

In addition to promoting effect, exosomes also have inhibitory effect on the growth of liver cancer.Hu et al. conducted experiments to study proliferation and migration and found that exosomes released by transgenic tumors had high transfection efficiency and reduced the activity of Wnt signaling pathway, thus inhibiting HCC (63). It has been suggested that some exosomal mirnas may function as tumor suppressors under specific circumstances. Exosomal miR-193-5p can inhibit the growth of HCC by targeting cyclin D1 and inhibiting the MAPK pathway (53). Although exosomes are generally considered promoters of HCC progression, several findings, especially regarding specific mirnas, such as miR-193-5p, suggest potential antitumor effects under specific conditions. Resolving these contradictions will be critical to translating exosome-based therapies into clinical practice.

Based on the relevant studies and experiments, exosomes play a multifaceted role in regulating cancer growth, including promoting tumor proliferation, angiogenesis, immune evasion, and drug resistance. These actions collectively provide favorable conditions for cancer growth and dissemination.

The immune system eliminates tumor cells, but some tumor cells are deceptive. Tumor-derived exosomes carry immunosuppressive substances, which are transmitted to immune cells and directly or indirectly inhibit the function of immune cells, thereby accelerating tumor development (64). This discovery determines the crucial role of exosomes in the development of tumor cells. Exosome PD-L1 can bind to the PD-1 receptor on T cells and inhibit the activation and proliferation of T cells, thereby helping tumor cells evade the attack of the immune system (65).

Meanwhile, some studies have found that high levels of exosomal PD-L1 are associated with poor response to immune checkpoint inhibitors(ICIs) such as PD-1/PD-L1 blockade therapy. Patients with elevated exosomal PD-L1 levels showed reduced responsiveness to PD-1 inhibitors, suggesting that these exosomes may serve as biomarkers to predict the efficacy of immunotherapy (53, 66). Many experimental studies have confirmed that by inhibiting the generation of exosomes in cancer and stromal cells, the growth and metastasis process of cancer can be effectively slowed down (67). Furthermore, Lu et al. recently proved that exosomes derived from head and neck squamous cell carcinoma (HNSCC) are taken up by tumor-associated macrophages (TAMs), thereby activating the NF-κB pathway in TAMs, thereby creating an immunosuppressive microenvironment conducive to tumor growth. Therefore, by inhibiting the phagocytic function of macrophages through CD73, it is expected to break the mechanism of tumor immune evasion and improve the therapeutic effect of tumors (68).

Elevated levels of circulating exosomal PD-L1 have been associated with reduced efficacy of ICIs like PD-1/PD-L1 blockers​ (69). Preclinical studies have shown that targeting exosomal PD-L1 can reverse immunosuppression and improve the efficacy of immunotherapy. In mouse models, inhibiting exosome release or neutralizing exosomal PD-L1 restores T-cell function and reduces tumor growth, improving the success of immunotherapy in patients who exhibit resistance (70). Combining exosomal PD-L1 inhibitors with standard immunotherapy is under investigation to improve patient outcomes. The focus of these trials is to assess how targeting exosomal PD-L1 can overcome HCC resistance to PD-1 inhibitors (71).

The ability to measure exosomal PD-L1 by liquid biopsy offers a non-invasive method to monitor the possibility of patient response to immunotherapy. This may allow for more personalized treatment planning, allowing clinicians to predict which patients are likely to benefit most from ICIs or alternative therapies (59). Exosomal PD-L1 not only promotes immune evasion in HCC, but also provides a potential biomarker for evaluating patient response to immunotherapy. This opens new avenues for integrating exosome analysis into clinical decision making for HCC treatment.

In the process of tumor cell migration, exosomes act as a key cell-to-cell communication medium, exerting important influence on each link in the chain reaction. This complex process includes the invasion behavior of tumor cells, their survival state in the blood vessels, and attachment and growth with host organs (72, 73).

Recent studies have shown that exosomal miR-3174 plays a key role in HCC progression and metastasis. According to Yang et al., miR-3174 can promote the deterioration of the disease by enhancing vascular permeability and inducing angiogenesis (52). One of the key exosomal miRNAs involved in HCC metastasis is miR-3174. Recent studies have shown that miR-3174 enhances vascular permeability by targeting the tight junction protein ZO-1, disrupting endothelial barrier integrity. This breakdown in vascular structure allows tumor cells to intravasate into the bloodstream, facilitating metastatic spread. Furthermore, high levels of exosomal miR-3174 correlate with increased metastatic potential and poor prognosis in HCC patients (74, 75). Another critical miRNA is miR-21, which is enriched in HCC-derived exosomes. Exosomal miR-21 promotes tumor progression by reprogramming the tumor microenvironment, particularly through its interaction with CAFs. miR-21 drives CAFs to secrete VEGF, enhancing angiogenesis and supporting metastasis (76). Exosomal proteins like TGF-β also contribute to HCC metastasis. Exosomes containing TGF-β can activate stromal fibroblasts, promoting the secretion of matrix metalloproteinases (MMPs) that degrade the extracellular matrix and enhance the invasive ability of HCC cells (77). This exosomal-mediated stromal remodeling is a critical step in enabling metastatic dissemination. Xiaopeng et al. found that under acidic conditions, the metabolic pathway of cancer cells changes, leading to an increase in the number of exosomes released by liver cancer cells and the expression level of functional miRNAs (such as miR-21 and miR-10b), further promoting the proliferation and metastasis of cancer cells (46). Lumin Wang and others found that HOXD3 was proven to target the promoter region of CCR6 and induce its transcription, thereby being delivered to endothelial cells through exosomes and promoting tumor migration. Zhuo-Zhen Lyu and others found that exosomes regulate the expression of miRNAs (such as miR-148a-3p) and target genes (such as MTF-1) by delivering specific non-coding RNAs (such as circ563), thereby affecting the biological behaviors of hepatocellular carcinoma cells (78). Lu et al. found that the level of miR-23a-3p in exosomes derived from M2 macrophages was higher, further promoting the proliferation and metastasis of HCC. These exosomes regulate target genes such as phosphatase and tensin homolog (PTEN) and tight junction protein 1 (TJP1) expression, and stimulate tumor cells to secrete more growth factors and chemokines, thereby promoting the malignant progression of tumors (79). Liu et al. found that exosomes could activate or inhibit specific signaling pathways, such as MAPK/ERK and PDK1/AKT, thereby regulating the proliferation, migration, and metastasis of hepatocellular carcinoma cells (80).

Additionally,EMT has been demonstrated to play a crucial role in the progression of lung cancer from initiation to metastasis. EMT is also associated with various other molecular processes, including tumor immune evasion, as well as the abundance of immune-suppressive cells and the expression of immune checkpoints in liver cancer cells (81, 82). Some studies have indicated that exosomes participate in EMT-related processes by serving as mediators of communication. Huang et al. experimentally identified the pyruvate dehydrogenase complex as a key substrate for activating EMT, demonstrating that the combination of EMT and autophagy inhibitors significantly enhances the therapeutic efficiency of liver cancer in vitro and in mice. Exosomes derived from liver cancer cells can induce EMT by activating the TGF-β/Smad signaling pathway, leading to decreased expression of E-cadherin and increased expression of vimentin to promote the migration and invasion of target cells (83). Chen et al. found in their research that exosomes from highly metastatic MHCC 97 H cells can communicate with low-metastatic liver cancer cells, enhancing their role in the EMT process. Furthermore, exosomes derived from liver cancer cells carry β-catenin, thereby inhibiting EMT and metastasis in HCC. Given the pivotal role of exosomes in metastasis, targeting exosome biogenesis and release offers a promising therapeutic approach. For example, GW4869, a neutral sphingomyelinase inhibitor, has been shown to inhibit exosome production. Future studies could explore the efficacy of exosome inhibitors like GW4869 in preventing HCC metastasis in vivo ( 84).

In summary, exosomes play a crucial role in HCC metastasis by facilitating cell-to-cell communication and promoting key processes such as angiogenesis, tumor cell migration, and EMT. Specific exosomal miRNAs, including miR-3174 and miR-21, have been identified as major drivers of metastasis (85). miR-3174 enhances vascular permeability to promote tumor cell dissemination, while miR-21 reprograms the tumor microenvironment by interacting with CAFs to stimulate angiogenesis (86). Additionally, exosomal proteins like TGF-β contribute to stromal remodeling and increased tumor invasiveness. Exosomes also regulate key signaling pathways such as MAPK/ERK and PDK1/AKT, further driving the metastatic progression of HCC (87). Targeting exosome biogenesis and release, as well as specific exosomal cargo like miR-3174 and miR-21, presents a promising therapeutic approach to prevent HCC metastasis (88).

Nowadays, exosomes are being used as valuable biomarkers for diagnosing and predicting various types of cancer due to their own properties and composition. The exosomes contain a variety of functional molecules, including proteins, lipids, DNA, various RNAs, and metabolites (89). Among these, proteins and ncRNAs are the most abundant substances in exosomes. Therefore, when referring to them as biomarkers, their value and utility are greater than those of other substances and are more widely used (90).

Under the protection of phospholipid bilayer membrane, exosomes cannot be degraded by any enzyme, and exosomes are considered to be suitable diagnostic tools.Researcher Lee et al. reported that the lncRNA-ATB contained in the serum exosomes of HCC patients was positively correlated with the TNM staging and volume of the tumor and negatively correlated with OS (91). Sohn et al. found that the levels of miR-18a, miR-221, miR-222, and miR-224 in the exosomes produced by HCC patients were lower than those of HBV patients.Therefore, exosomes can be used as independent markers for the diagnosis and prognosis of HCC.

In the detection of exosomes, several studies have used nucleic acid detection methods that can distinguish between patients and healthy individuals by detecting samples from plasma. Although this detection method is more expensive, it still has great potential in clinical applications (92). The clinical and research experiments mentioned above all indicate that exosomes can serve as reliable biomarkers for cancer detection and diagnosis of its type (84). Exosome proteins have a greater potential for use in cancer diagnosis, while exosome non-coding RNA plays a more important role in predicting various types of cancer. Their role in carrying specific molecular signatures, such as miRNAs, proteins, and non-coding RNAs, makes them valuable tools for monitoring disease progression and response to treatment. However, while their potential is compelling, several challenges must be addressed to translate these findings into routine clinical practice.

One of the key challenges in utilizing exosomes as clinical biomarkers is the standardization of detection methods. Currently, exosome isolation techniques such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture vary widely in terms of efficiency, purity, and reproducibility (93). Another significant challenge is the variability in exosome content among patients. Exosomal cargo is influenced by several factors, including tumor heterogeneity, disease stage, and even the patient’s immune response, which may result in significant variability in exosomal biomarkers across individuals (94). Furthermore, there is the issue of EV heterogeneity, where exosomes are just one subtype among many EVs. This complicates biomarker studies, as differentiating between exosomes and other EVs is challenging, yet crucial for the specificity of diagnostic tests (95) (Table 2).

Although AFP is widely used in clinical practice, it has significant limitations in terms of sensitivity and specificity, especially in early-stage HCC. Exosome-based biomarkers have been shown to be superior to conventional serum AFP in detecting early HCC and predicting outcome. For example, exosomal mirnas such as miR-21, miR-122, and miR-155 can provide insight into tumor behavior and perform noninvasive detection with higher diagnostic accuracy (101–103). However, there are many challenges to integrating exosome biomarkers into routine clinical practice. In contrast, AFP testing is mature, cost-effective, and widely available, but it often fails to detect early-stage HCC and can produce false positives, especially in patients with chronic liver disease (104–106) (Table 3).

Some researches have found that microRNAs are a key mechanism component of tumor-derived Exosomes in executing their functions, and exosomes have been determined as an important medium for communication between tumor cells and the microenvironment (107). Exosome microRNAs are highly abundant in exosomes and are associated with immunoregulation, chemotherapy resistance, and metastasis of various tumor types (108). The influence of exosome microRNA on the liver microenvironment and its role in GC-LM are significant. Some researchers have found that miRNAs account for about 43% of the RNA in exosomes, and play an important role in the biological regulation function of exosomes. Exosome miRNA has also been proven to participate in organ-specific metastasis of various cancers, including lung cancer, breast cancer, pancreatic cancer, and melanoma, by reshaping the target organ microenvironment (109).

Exosome microRNA has been applied in the clinical treatment of autoimmune diseases. A related study shows that the exosomal microRNA released by Tlymphocytes in rodents and humans can transfer to beta cells in an active form, leading to beta cell apoptosis (110). According to recent research findings, exosomes can promote cancer progression by mediating miRNA communication between tumor cells and surrounding cells, thereby affecting tumor angiogenesis. In addition, detecting circulating exosomal miRNA in serum for cancer diagnosis has been proven to be a reliable method.

Exosomal miRNAs are heavily implicated in HCC’s progression by regulating gene expression in recipient cells. For example, miR-21 in HCC-derived exosomes is known to facilitate tumor progression by transforming hepatic stellate cells into CAFs, which then promote tumor growth and metastasis (86). Another significant miRNA, miR-122, a liver-specific miRNA, is under-expressed in HCC exosomes. Restoring its expression has been shown to suppress tumor growth by regulating metabolic pathways, such as the Warburg effect, and inhibiting the PI3K/Akt pathway (111).

Combining the above review, microRNA provides diagnostic biomarkers and valuable therapeutic targets, which can serve as potential diagnostic or prognostic biomarkers in the tumor microenvironment and have great potential (112) (Figure 3).

Exosome proteins are proteins that are packed inside or embedded on the surface of exosome membranes, and are an extremely important exosome transport protein (7). Exosome proteins have become a potential important source of biomarkers for observing exosome production, targeted therapy, and cancer diagnosis and prediction. Exosomal proteins also play a role in regulating the treatment of tumor-related processes (113). Many experiments have demonstrated that exosomal proteins play an important role in tumor therapy, angiogenesis, epithelial-mesenchymal transformation, tumor microenvironment and drug resistance research. However, the interaction mechanism between exosomal proteins and hepatocellular carcinoma therapy is rarely studied (114).

Exosomal proteins consist of various types, including MHC, tetraspanins, various enzymes, glycoproteins, as well as a range of ligands and receptors (21). These exosomal proteins provide sufficient diagnostic, monitoring and prognostic information for the treatment of liver cancer (115). Arbelaiz et al. compared the protein levels in exosomes from liver cancer patients and healthy cohorts in the study and found that exosomal G3 BP can better diagnose liver cancer and differentiate it from other liver diseases. Fu et al. reported in their study that SMAD 3 protein is present in exosomes derived from liver cancer cells and is positively correlated with the pathological grade of liver cancer. Wang et al. reported in their study that the level of 14-3-3 protein in exosomes derived from liver cancer cells increases, and 14-3-3 protein can weaken the anti-tumor activity of T cells.

Exosomal proteins play a critical role in intercellular communication and remodeling the tumor microenvironment. For instance, proteins like HSP70 and EGFR are highly expressed in HCC-derived exosomes, promoting cancer cell migration and invasion (116, 117). These proteins also contribute to the development of drug resistance by altering the surrounding stroma, making them key players in HCC progression and therapeutic resistance.

The most important role of exosome proteins in cancer treatment is drug delivery. By engineering the surface proteins of exosomes, drugs and therapeutic agents can be directly packaged into exosomes, thereby achieving higher efficiency (118). Xu et al. evaluated in their paper that the immune function of exosomes may make them specific drug delivery tools or vaccines for cancer immunotherapy (119). In summary, exosome proteins play a key role as biomarkers in the prediction and diagnosis of various cancers, can be used as drug delivery carriers to selectively deliver drugs to designated cell receptors, and have good potential applications in these areas. However, the knowledge of the functions and applications of exosome proteins is still limited.

There are already some long non-coding RNAs (lncRNAs) that have been evaluated as playing important roles in the carcinogenesis and progression of liver cancer. The exosomes carrying lncRNAs from HCC cells have been identified as key mediators for the treatment of HCC (120). lncRNA H19, transferred via exosomes, enhances the invasiveness of HCC cells by interacting with miRNAs and influencing the tumor microenvironment (121). Similarly, lncRNA TUC339 promotes the proliferation and migration of HCC cells by modulating various signaling pathways (122).

Wang et al. found in their study that a novel lncRNA was overexpressed in hepatocellular carcinoma by using qRT-PCR and fluorescence in situ hybridization, and it was positively correlated with the predictive index of cancer, thus being a novel oncogenic lncRNA (123). Furthermore, M. Xu et al. confirmed in their experiment that incMMPA (an lncRNA) could regulate the tumor of HCC through immunohistochemical analysis and fluorescence, and it could increase the proliferation of HCC cells by interacting with miR-548 s in vivo (124). H. Cha et al., in their study, also evaluated a novel regulatory factor that modulates hepatocarcinogenesis through lncRNA-HEIH, which may serve as a potential therapeutic target for hepatocellular carcinoma (125). In summary, lncRNAs from exosomes have great potential for the proliferation of hepatocellular carcinoma and its treatment, and can be used as a key mediator for the treatment of liver cancer.

The exosomal lipids refer to the biologically active lipids carried by exosomes, which have great potential to be used as liver delivery vehicles and cancer agents targets. Exosomal lipids contribute to both the structural stability of exosomes and the regulation of metabolic processes in recipient cells. Lipids like sphingomyelin and cholesterol are known to facilitate communication between HCC cells and are implicated in drug resistance mechanisms. By influencing metabolic pathways, exosomal lipids could offer new biomarkers for early detection and therapeutic targets (126). Both artificially synthesized liposomes and naturally derived exosomal lipids are ideal drug delivery carriers (127). In addition, exosomal lipids have good functionalities in targeted therapy and natural affinity to liver cells (128). Some studies have evaluated the above functions of exosomal lipids.

Tabernero and colleagues first achieved liver cancer targeted therapy by using exosomal lipids as drug delivery carriers in phase I studies. Some researchers evaluated in the experiment the ability of exosomal lipids loaded with miR-375 and sorafenib to inhibit autophagy process and reduce tumor burden to achieve high efficiency and stability in treatment (129). Woitok et al. delivered exosomal lipids loaded with siRNA targeting Jnk 2 to mice with chronic liver disease, showing a reduction in precancerous nodules in liver cells and a benign shift in the cancer microenvironment (130).

In conclusion, exosomal cargo, including micrornas, proteins, lncrnas, and lipids, plays a multifaceted role in HCC biology and progression. Exosomal micrornas contribute to immune regulation, chemotherapy resistance and metastasis in regulating gene expression. For example, miR-21 and miR-122 affect HCC growth and tumor microenvironment (86, 111). Exosomal proteins such as HSP70 and EGFR are involved in cancer cell migration, invasion and drug resistance, and can be used as potential biomarkers for diagnosis and targeted drug delivery (116, 117). Exosomal lncrnas, such as H19 and TUC339, enhance HCC cell invasiveness and proliferation by interacting with mirnas and altering signaling pathways (122). Finally, exosome lipids contribute to the structural stability of exosomes and regulate the metabolic processes of recipient cells, which are promising targets for drug delivery and liver-specific therapy. Collectively, these exosome components provide a dynamic network that influences HCC progression, providing potential diagnostic biomarkers and therapeutic targets (126).

In the treatment of liver cancer, exosomes are used to deliver RNA complexes of viruses to liver cells, which are then used by T cells to suppress immune responses. And exosomes can be used as independent tumor markers in the assessment of HCC staging, efficacy, and prognosis. Therefore, exosomes play a key role in the occurrence, diagnosis, and treatment of HCC and have broad clinical applications (131).

Some researchers have shown that exosomes can affect the growth and metastasis of liver cancer cells by secreting substances for regulation (3). Additionally, some researchers have found that, in addition to liver cancer cells, other cells can also secrete exosomes to promote the growth of liver cancer cells and reduce DNA damage (132).

Camel milk exosomes show therapeutic potential, particularly in slowing breast cancer progression by inducing apoptosis and reducing oxidative stress, inflammation, and metastasis, with local injection proving more effective than oral use.They also enhance the effects of tamoxifen in chemotherapy and, when combined with chitosan nanoparticles and sorafenib, significantly reduce tumor burden in cancer models. Additionally, camel milk proteins exhibit immunomodulatory and antioxidant properties (15, 133–138). Curcumin and ginger-derived exosomes reduce inflammatory cytokines in the tumor microenvironment, suppressing cancer progression (57). In the treatment of liver cancer, Tcm-derived exosomes can inhibit cell proliferation by regulating cell cycle and inducing apoptosis, anti-inflammation by inhibiting pro-inflammatory cytokines and regulating immune response, anti-oxidation by scavenging free radicals and regulating antioxidant enzyme activity, and reducing liver fibrosis by inhibiting hepatic stellate cell activation and regulating extracellular matrix metabolism (139–142).

Therefore, using exosomes to trigger anti-tumor immunity has become a promising therapeutic strategy (142). Exosomes play a key role in the occurrence, diagnosis, and treatment of hepatocellular carcinoma, and many of its substances, such as mRNA, can serve as new biomarkers, laying a foundation for subsequent research and clinical applications.

In summary, the application of exosomes in liver cancer has attracted much attention in the field of tumor therapy. Exosomes can deliver drugs to target organs and cells in the body more efficiently by encasing drugs in exosomes, thereby reducing side effects and enhancing therapeutic effectiveness. In this paper, we review that exosomes play a multifaceted role in regulating cancer growth, including promoting tumor proliferation, angiogenesis, immune evasion, and drug resistance, actions that together provide favorable conditions for cancer growth and spread. Therefore, the study of exosomes is of great significance for revealing the pathogenesis of cancer and developing new therapeutic strategies.

In addition, cell-derived exosomes can be used to estimate biomarkers for various cancer diagnoses, predictions, therapeutic efficacy, and outcomes. Exosomal RNA, DNA, proteins, lipids and other substances provide valuable therapeutic targets for the treatment of hepatocellular carcinoma and serve as potential diagnostic or prognostic biomarkers in the microenvironment of liver cancer. However, the current understanding of the function and application of exosomal proteins is still limited. Exosomes still have some technical, functional and safety issues that need to be addressed. Firstly, the development of more reliable and efficient exosome isolation techniques is the key to ensure high purity and yield, which is essential for basic research and clinical translation. Secondly, exploring the heterogeneity of exosomes is crucial to fully understand their different roles in liver cancer and to exploit this diversity to obtain treatment. Finally, the clinical translation of exosome-based therapies needs to be rigorously validated in human trials to address issues of safety, efficacy, and scalability.

Despite these challenges, the prospect of using exosomes for the treatment of liver cell tumors is still very promising. As technology continues to advance, these challenges will be overcome one by one, and exosomes will become an important tool for tumor treatment. It is believed that exosomes will be widely used in the treatment of liver cancer in the future.